First Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not Always

Similar documents
2 Brigham and Women s Hospital, Boston, MA.

Aortic valve implantation using the femoral and apical access: a single center experience.

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

Successful Transfemoral Edwards Sapien Aortic. Valve Implantation in a Patient with Previous. Mitral Valve Replacement

2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route

Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved

Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?

Imaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013

Transcatheter aortic valve replacement in high risk patients with different anaesthetic techniques

Transcatheter aortic valve implantation (TAVI): an example of how to organise a TAVI programme

Transcatheter Aortic Valve Implantation Management of risks and complications

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Preprocedural evaluation for TAVR

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and

Disclosures. ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech

Bioprosthetic Mitral Valve Dysfunction: Innovation and Evolution of a New Therapeutic Technique

Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know

Transcatheter Aortic Valve Implantation Using CoreValve by Transaortic Approach

The Acute and 3-Month Outcomes of Transcatheter Aortic Valve Implantation in Taiwan

Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry

Results of Transapical Valves. A.P. Kappetein Dept Cardio-thoracic surgery

Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval?

Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC

Percutaneous Valve Interventions. Percutaneous Valve Interventions

Severity of AS Degree of AV calcification (? Bicuspid AV), annulus size, & aortic root

Percutaneous Therapy for Calcific Mitral Valve Disease

Why do we need percutaneous

The Colibri heart valve: theory and practice in the achievement of a low-profile, pre-mounted, pre-packaged TAVI valve

TAVR SPRING 2017 The evolution of TAVR

REVIEW ARTICLE Transcatheter aortic valve insertion: anaesthetic implications of emerging new technology

Minimalist Transcatheter Aortic Valve Replacement (MA-TAVR)

Transcatheter Aortic Valve Replacement

Objective: The authors report the first experience made in our midst with the use of the CoreValve endoprosthesis.

VALVULOPATIE: NUOVE SOLUZIONI.

Incidence And Predictors Of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation

TRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH

Severe left ventricular dysfunction and valvular heart disease: should we operate?

Contemporary trans catheter treatment of severe aortic stenosis

Nouvelles indications/ Nouvelles valves

Para-valvular Leak Closure

Heart Team For TAVI Who and How?

Affiliation/Financial Relationship Grant/ Research Support: Major Stock Shareholder/Equity Interest: Royalty Income: Ownership/Founder: Salary:

1-YEAR OUTCOMES FROM JOHN WEBB, MD

Successful percutaneous treatment of late-onset femoral pseudoaneurysm after transcatheter, aortic valve implantation procedure

TRANSAPICAL AORTIC VALVE REPAIR

Index. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type.

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40

Transapical transcatheter aortic valve implantation: Follow-up to 3 years

Introducing transcatheter aortic valve implantation with a new generation prosthesis: Institutional learning curve and effects on acute outcomes

TAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:

22/06/2017. Oxford City. Transcatheter aortic valve replacement 2017 guidelines. 1. First time I have heard about it. 2.

Emergency TAVI: Does It Exist? Is the Risk Higher?

Six-month outcome of transapical transcatheter aortic valve implantation in the initial seven patients

Transcatheter CoreValve valve-in-valve implantation in a stentless porcine aortic valve for severe aortic regurgitation

New York Valves Patient focused evidence-based approach. New York City: 6 December Antonio Colombo

PERCUTANEOUS TRANSLUMINAL MITRAL VALVULOPLASTY IN POST MITRAL VALVE REPAIR AND AORTIC VALVE REPLACEMENT PATIENT

Transcatheter aortic valve implantation for aortic stenosis

Percutaneous Coronary Intervention and Pulmonary Balloon Valvuloplasty in a Patient With Severe Valvular Pulmonary Stenosis

How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min

Transcatheter aortic valve implantation and pre-procedural risk assesment

Prince Sultan Cardiac Center Experience Riyadh, Saudi Arabia

Structural Heart Disease Transcatheter Aortic Valve Replacement (TAVR)

APOLLO TMVR Trial Update: Case Presentation

TAVR: It s a Career, Not Just a Procedure! Jeffrey A Southard, MD Cardiology May 5, 2012

Transcatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee

Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system

Jonathon Leipsic MD FRCPC FSCCT. Vice Chairman of Radiology University of British Columbia. Disclosures

Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France

New Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor. Cardiothoracic Radiology

Aortic Valve Implantation

TAVI complication. Possible aetiology and how to manage

BroadcastMed Grand Rounds: Transcatheter Aortic Valve Replacement

Department of Cardiology, Onassis Cardiac Surgery Centre, Athens, 3 Department of Anaesthesiology, Hippokration Hospital, Athens, Greece

Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris

Results of Transfemoral or Transapical Aortic Valve Implantation Following a Uniform Assessment in High-Risk Patients With Aortic Stenosis

TAVI at Liverpool Heart & Chest Hospital. National Audit of Cardiac Services in Wales Wrexham 28/11/2012

Conflicts of interests

Procedural Guidance of TAVR: How to Assure it Goes Right and What to Do If It Doesn t

Case Presentations TAVR: The Good Bad and The Ugly

Corrado Tamburino, MD, PhD

Transcatheter Aortic Valve Replacement with Evolut-R

TAVI: 10 Years After the First Case Low-Risk and High-Risk Patients What are the Limits? Dr Bernard Prendergast DM FRCP FESC John Radcliffe Hospital

TAVR and Cardiac Surgeons

How to manage device embolization?

Conflicts of interests

Boston, MA 2 Service Chief, Cardiovascular Imaging, Department of Radiology, Massachusetts General Hospital,

Improvements in quality of life in septuagenarians versus octogenarians undergoing trans-catheter aortic valve replacement

Policy Specific Section: March 30, 2012 March 7, 2013

Valvular Guidelines: The Past, the Present, the Future

Interventional procedures guidance Published: 26 July 2017 nice.org.uk/guidance/ipg586

Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid

The learning curve associated with transapical aortic valve implantation

Transaortic Transcatheter Aortic Valve Implantation as a second choice over the Transapical access. Ropponen, J.

Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes

Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter

TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre

CASE PRESENTATION CASE REPORT

IMAGES. in PAEDIATRIC CARDIOLOGY

Zanobini et al. Journal of Cardiothoracic Surgery (2017) 12:114 DOI /s

Transcription:

ISPUB.COM The Internet Journal of Cardiology Volume 9 Number 2 First Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not T D, J P. Citation T D, J P.. First Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not. The Internet Journal of Cardiology. 2009 Volume 9 Number 2. Abstract Degenerative aortic stenosis is one of the most common valve diseases in the elder generation.(5) Age and comorbidities often lead to unacceptably high perioperative risk and a number of these patients are refused surgery and left on medical therapy with a very poor quality of life as well as life expectancy.(4,8,9) Development of an alternative method of treatment is very important for these patients(1,2,).the case we are reporting is the first case of THV in Bulgaria INTRODUCTION Degenerative aortic stenosis is one of the most common valve diseases in the elder generation.(5) Age and comorbidities often lead to unacceptably high perioperative risk and a number of these patients are refused surgery and left on medical therapy with a very poor quality of life as well as life expectancy.(4,8,9) Development of an alternative method of treatment is very important for these patients(1,2,). Figure 1 fig. 1. Very calcified aortic stenosis The case we are reporting is the first case of THV in Bulgaria CASE REPORT A 70-year-old man presented with symptomatic severe AS, and worsening functional status NYHA class III - IV, over a six month period. Comorbidities: chronic renal failure (HRF) gr. II, anemia, severe pulmonary hypertension. ECG showed atrial fibrillation, LBB. Echocardiographic assessment showed severe AS with an aortic valve area 0,7 cm2 and a mean pressure gradient of 70 mmhg across a heavily calcified aortic valve. The aortic annulus measured 20 mm in diameter. There was moderate mitral regurgitation (MR). Left ventricular ejection fraction (LVEF) was 24%.Cardiac catheterization showed heavily calcified aortic valve,clear coronary and carotid arteries.(fig.1. fig 2.) 1 of 5

Figure 2 fig.2 Clear coronary arteries obtained for the placement of a pacing wire in the right ventricular apex and pigtail catheter in the aortic root. Surgical cut-down of the right external iliac artery was performed, and a size 14-French sheath was inserted. The valve was crossed using standard retrograde technique. A long stiff 0,035-inch wire was placed in the left ventricular apex. Balloon valvuloplasty was successfully performed with a 23mm x 30 mm balloon under rapid ventricular pacing and decrease BP under 50 mm Hg.(fig 4.). Figure 4 fig.4. Balloon valvuloplasty aortic valve Mean pressure gradient was 65 mmhg. Ileofemoral angiogram showed patent non-tortuous iliac and femoral arteries.(fig.3.) Figure 3 fig.3 Aorto-iliac angiogram 24-French sheath was inserted and 26 mm Sapien THV(Edwards Lifesciences) was then manually crimped onto 26 mm x 3 cm balloon and advanced to the aortic annulus. The logistic EuroSCORE was 27% and STS 6,1 The novel technique of percutaneous aortic valve implantation was offered as a alternative to surgical AVR. Even after predilatation, crossing the aortic valve with the prosthesis turned to be impossible After several unsuccessful attempts we decided to predilate once more. Keeping the THV device in the ascending aorta we placed a 14-french sheath in the left femoral artery, passed the predilatation balloon through it and dilated the valve again( fig 5). Informed consent was obtained from the patient and family. The procedure was performed in the cardiac catheterization laboratory under general anaesthesia. A cannula was placed in the right radial artery for continuous blood pressure (BP) monitoring. Transoesophageal echocardiography (TEE) was performed to confirm aortic annulus dimension and to provide imaging during the procedure. Left arterial and venous accesses were 2 of 5

Figure 5 fig.5. Repeat balloon valvuloplasty aortic valve and attempt to cross the valve with the device Figure 7 fig.7. Stable THV position final result After another unsuccessful attempt to cross the valve with the device we decided to dilate again and simultaneously,using the moment of deflation and pulling out of the balloon trying to pass the device through the valve. This time we were successful. Optimal THV position was assessed with fluoroscopy and TEE.This THV was then deployed under rapid pacing by inflating the balloon.( fig 6). Figure 6 fig.6. Deployed THV The patient was extubated on-table. There is no peripheral complications. The patient was discharged and follow-up was every month by clinical examination end echocardiography.ten months after procedure the patient was well with marked improvement in functional status to NYHA class II. Echocardiographical assessment showed a LVEF 45%, a mean pressure gradient 16 mmhg across the aortic valve, aortic regurgitation I degr and MR below II degree. CONCLUSION Percutaneous aortic valve implantation is emerging as an alternative to surgical AVR for selected patients with symptomatic severe AS, who are at high surgical risk or are non-operable. The technology has evolved very rapidly with satisfactory results, mainly in major institution in Europe and USA( 6,7,10.) In this first for Bulgaria case of percutaneous transfemoral aortic valve implantation a patient with severe heavily calcified AS and high surgical risk was successfully treated, with good clinical result at 10-months follow-up. ACKNOWLEDGEMENT Immediately post-deployment TEE showed a stable THV position, a mean pressure gradient of 8 mmhg and trivial paravalvular leak. (fig 7) Root aortogram revealed minimal aortic regurgitation and patient coronary arteries The authors would like to thank Dr K Spargias, MD PhD, FESC from the Hospital Onassis Heart Centre, Athens for his technical assistance during the procedure. References 1. Cribier A, Eltchaninovf H, Bash A,et al.early expirienca with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. J Am Coll Cardiol 3 of 5

2004;43:698-703. 2. Cribier A, Eltchaninovf H,, Tron C, et al. Treatment of calcific aortic stenosis with the p,ercutaneous heart valve: mid-term follow-up from the initial feasibility studies: thje French experience. J Am Coll Cardiol 2006;47: 1214-1223. 3. Iung B, Bakon G,Butchart EG,Delahaye F, Gohlke- Barwolf C,Levang OW,Tormos P, Vanoverschelde JL,Vermeer F,Boersma E,Ravand P, Vahanian A. A perspective survey of patients with valvular heart disease. Eur Heart J 2003;24:1231-1243. 4. Otto CM, Burwash IG,Legget ME,Munt BI,Fujioka M,Healy NL, Kraft CD, Miyake-Hull CJ, Schwaegler RG, Prospective study of asymptomatic valvular aortic stenisis. Clinical,echocardiographic and exercise predictors of outcome. Circulation 1997;95: 2262-2270. 5. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovik DAssociation of aortic valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999;342:142-147. 6. Paniagua D,Condado JA,Besso J et al. First human case of retrograde transcatheter implantation of an aortic valve prosthesis. Tex Heart Inst J 2005;32: 393-398. 7. Melby SJ,Zierer A,Kaiser YP,et al. Aortic valve replacement in octogenarians. Risk factors for early and late mortality. AnnThorac Surg 2007;83:1651-1657. 8. Iung B, Baron G,Butchart EG,et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003;24: 1231-1243. 9. Karadarajan P,Kapoor N,Bansat RC,Pai RG. Clinical profile and natural hystory of 453 nonsurgically managed patients with severe aortic stenosis. Ann Thorac Surg 2006;82:2111-2115. 10. Eltchaninoff H,Zajarias A, Tron C, at al. Transcatheter aortic valve implantation: technical aspects,results and indications.arch Cardiovasc Dis 2008;101:126-32. 4 of 5

Author Information Trendafilova D University Hospital St.Ekaterina Jorgova J.Simeonov P. University Hospital St.Ekaterina 5 of 5